HomeAI · summaries
Storia in 3 fonti
US signals crackdown on compounded weight-loss drugs; Hims shares tumble
The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims & Hers.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
Novo Nordisk and Eli Lilly fell after Hims & Hers said it will offer a copy of the Wegovy pill for $49, far less than the $149 Novo sells the branded pill for.
- ·
Hims & Hers falls 8% after Novo's legal threat. Here's the latest
Hims & Hers stock fall to a 12-month low after Novo said it's $49 Wegovy pill copy was "illegal"
- ·
US signals crackdown on compounded weight-loss drugs; Hims shares tumble
The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims & Hers.
- ·
Hims & Hers pulls copycat weight-loss pill after threats of legal action
Hims & Hers on Saturday announced it would stop offering its copycat of the weight-loss pill Wegovy after threats of legal action.
- ·
fortune.com
Hims & Hers scraps copycat Wegovy weight-loss pill after probe | Fortune
The announcement comes a day after the US Food and Drug Administration said it was cracking down on copycat weight-loss treatments.
- ·
Novo Nordisk pops 8% after Hims & Hers pulls copycat weight-loss pill
Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market.
- ·
Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections
Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is seeking to recover damages.
- ·
ft.com
Novo Nordisk sues Hims & Hers over copycat weight-loss drugs
Shares in US company fall 16% after FDA announces investigation into unregulated medication